Overview

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.

Phase:

Phase 3

Details

Lead Sponsor:

Alkermes, Inc.

Treatments:

Aripiprazole
Aripiprazole lauroxil